Key result
Switching from TEE to TLD linked to higher rates of new hypertension and CKD.
Why the study?
Does switching from an efavirenz-based to a dolutegravir-based antiretroviral regimen increase the risk of cardiovascular, metabolic, and renal complications in people living with HIV?
Cohort (n=212)
No
Does switching from an efavirenz-based to a dolutegravir-based antiretroviral regimen increase the risk of cardiovascular, metabolic, and renal complications in people living with HIV?
Answers are grounded in this paper and cite their sources.
Switching from efavirenz-based to dolutegravir-based antiretroviral therapy in HIV patients is associated with increased rates of new-onset hypertension and chronic kidney disease, highlighting the need for metabolic and renal monitoring.
BACKGROUND: Dolutegravir (DTG) became central to South Africa's (SA's) first-line human immunodeficiency virus (HIV) regimen since 2019, offering improved tolerability, fewer drug-drug interactions, and a higher resistance barrier compared to efavirenz (EFV). Concerns remain about the long-term cardiovascular, metabolic, and renal consequences of DTG-based therapy in people living with HIV (PLHIV). This study compared demographic and clinical outcomes across three groups: (1) those on tenofovir, emtricitabine and efavirenz (TEE); (2) those on tenofovir, lamivudine and dolutegravir (TLD); and (3) those switched from TEE to TLD. METHODS: This retrospective, analytical study was conducted at an urban district hospital in KwaZulu-Natal. A sample of 212 patients was calculated using a chi-squared test for multiple proportions (80% power, 95% confidence interval). Data extracted at baseline, 6 and 12 months, were analysed with SPSS version 28.0. RESULTS: There were statistically significant differences between the three groups. The Switch group showed a higher incidence of new hypertension (HT) (9.9%, p = 0.03) and chronic kidney disease (CKD) (12.1%, p = 0.01). TLD group maintained stable outcomes. TEE group had the highest incidence of newly diagnosed dyslipidaemia. CONCLUSION: DTG-based therapy remains the preferred regimen in SA, its long-term metabolic and renal impact in patients switching from EFV warrants careful surveillance. The increased rates of HT and CKD in the Switch Group emphasises the need for closer monitoring to mitigate against complications.Contribution: This research contributes to the body of evidence on DTG, highlighting its benefits and the clinical challenges of managing ageing PLHIV with multimorbidity.
No takes yet. Share an insight, caveat, or question.
Kimberley et al. (2025) conducted a cohort in Human immunodeficiency virus (HIV) (n=212). Switching from TEE to TLD vs. TEE and TLD groups was evaluated on Incidence of new hypertension (HT) (p=0.03). Switching from TEE to TLD in HIV patients was associated with a higher incidence of new hypertension and chronic kidney disease.
Synapse has enriched 10 related papers. Consider them for comparative context: